Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R ...

Cartesian Therapeutics has initiated a phase 1 trial for Descartes-15, a next-gen autologous mRNA-engineered CAR-T therapy targeting BCMA for relapsed/refractory multiple myeloma, featuring predictable pharmacokinetics and enhanced CAR stability, with outpatient delivery potential. Preclinical data shows Descartes-15 outperforming Descartes-08 in CAR expression and target-specific killing. The trial aims to assess safety and tolerability, with plans to expand to autoimmune disease treatment.